1AC Value Morality Criterion Maximizing Well Being 1C Increasing Covid-19 Vaccination Rollout in Developing Countries 2C Increasing Gender Equality
1NC Value Morality Criterion Preserving Human Lives 1C Decreasing Innovation SubA Covid-19 2C IPR reduction would increase counterfeits
Won't be posting cites as I have identical sites to those used in previous rounds
Little Rock Central
1
Opponent: JPG Dozda | Judge: Adicherla, Shreyas
1AC Value Common Good Crit Human Welfare 1C Covid-19 2CInsulin
1NC Value Morality Crit Preserving Human Lives 1C Increasing Innovation Sub-A Covid-19 2C Counterfeit Drugs
Little Rock Central
3
Opponent: JPG Lagneaux | Judge: Breckenridge, Andrea
1AC Value - Morality Crit Upholding Human Rights 1C Insulin 2C Covid-19 3C Monopolies
1NC 1NC Value Morality Crit Preserving Human Lives 1C Increasing Innovation Sub-A Covid-19 2C Counterfeit Drugs
The Ed Long Invitational at The Hockaday School
1
Opponent: Coppell NP | Judge: Berdugo, Erick
1AC Value Morality Crit Minimizing structural violence Explanation on why structural violence is bad C1 Racial Inequality Strikes strengthen union action which helps struc violence get solved Has a second contention but ran out of time
1NC Value Justice Criterion Consequentialism Burden Aff must prove that they can keep the right unconditional C1 Economic Harms from striking C2 Hospital Strikes C3 Resolution impossible under aff
To modify or delete round reports, edit the associated round.
But what is even more important than what’s possible under a robust intellectual property system, is what’s impossible without it. First: continued research and development. It takes decades and often costs billions to bring a new medicine to market. The timeline for COVID-19 vaccine deployment in 2020 has been nothing short of miraculous – and it would have been impossible absent the decades of research investment it built upon. Additionally, for every 25,000 therapeutic compounds that start in the laboratory, 25 make it to clinical trial, 5 make it to market, and only one recoups the cost invested. Intellectual property protections signal to innovators and investors that shouldering this risk is worth it. Intellectual property protections promise that new ideas have tangible value. Without that signal and that promise, the business of innovation isn’t viable. Second: build-on innovation. The intellectual property system – specifically, the patent system – promotes the public disclosure of inventions, which encourages further discovery. When an innovator applies for a patent, they’re required to describe how their invention works and what it can do. The innovator’s discovery is respected for a period before transitioning into the public domain. That means, every time a patent is granted, the global innovation knowledge pool gets a little bigger. On the flip side, if countries quit respecting patents, the global innovation information pool dries up, knowledge contracts and the amount of private investment in RandD will inevitably shrink. Finally: A safe, legitimate marketplace. Patents facilitate a market for innovative medicines, throughout the development stage, as well as in commercialization. Licensing arrangements facilitate the types of collaborations that have proven so successful in 2020; they also ensure that third-party manufacturers are making, using, and selling COVID-19 solutions safely and ethically. Without it, counterfeiters and other bad actors could put shoddy, unreliable, and downright dangerous dupes on the market, all the while marketing them as legitimate products. It’s literally a matter of life and death: Thousands, if not millions, of people die each year at the hands of counterfeit drugs.
Developing a new prescription medicine that gains marketing approval is estimated to cost drugmakers $2.6 billion according to a recent study by Tufts Center for the Study of Drug Development and published in the Journal of Health Economics. This is up from $802 million in 2003—equal to approximately $1 billion in 2013 dollars, and thus a 145 percent increase in the ten year study gap. Furthermore, while the average time it takes to bring a drug through clinical trials has decreased, the rate of success has gone down by almost half, to just 12 percent.
Developing a new prescription medicine that gains marketing approval is estimated to cost drugmakers $2.6 billion according to a recent study by Tufts Center for the Study of Drug Development and published in the Journal of Health Economics. This is up from $802 million in 2003—equal to approximately $1 billion in 2013 dollars, and thus a 145 percent increase in the ten year study gap. Furthermore, while the average time it takes to bring a drug through clinical trials has decreased, the rate of success has gone down by almost half, to just 12 percent.
Tournament: Little Rock Central | Round: 1 | Opponent: JPG Dozda | Judge: Adicherla, Shreyas St. Francis School of Law, 4-15-2021, "Intellectual Property Rights: Definition and Examples," St Francis School of Law, https://stfrancislaw.com/blog/intellectual-property-rights/
The definition of intellectual property rights is any and all rights associated with intangible assets owned by a person or company and protected against use without consent. Intangible assets refer to non-physical property, including right of ownership in intellectual property
9/25/21
IPR Def
Tournament: Little Rock Central | Round: 3 | Opponent: JPG Lagneaux | Judge: Breckenridge, Andrea St. Francis School of Law, 4-15-2021, "Intellectual Property Rights: Definition and Examples," St Francis School of Law, https://stfrancislaw.com/blog/intellectual-property-rights/
The definition of intellectual property rights is any and all rights associated with intangible assets owned by a person or company and protected against use without consent. Intangible assets refer to non-physical property, including right of ownership in intellectual property
In addition to functioning as a tool to maintain constant innovation in the industry, IP helps reduce counterfeit medicines because medicines have better technologies and ingredients are more difficult to copy. This means that, through market incentives, the industry manages to have high quality infrastructure, new technology and trained personnel, to create specialized and specific medicines and therapies, which is why they are difficult to replicate. On the other hand, political will functions as another important axis, as it must prosecute those who are making counterfeit medicines. This is achieved through a constant conversation between industry and governments. Therefore, it will be absolutely clear how to identify the authenticity of medicines. In short, IP allows quality standards to be clearer and stricter, and regulators to have greater knowledge and traceability of each product that enters the market. Through IP, you can establish a record of all products globally, which makes it easier to find possible counterfeit medicines.
In addition to functioning as a tool to maintain constant innovation in the industry, IP helps reduce counterfeit medicines because medicines have better technologies and ingredients are more difficult to copy. This means that, through market incentives, the industry manages to have high quality infrastructure, new technology and trained personnel, to create specialized and specific medicines and therapies, which is why they are difficult to replicate. On the other hand, political will functions as another important axis, as it must prosecute those who are making counterfeit medicines. This is achieved through a constant conversation between industry and governments. Therefore, it will be absolutely clear how to identify the authenticity of medicines. In short, IP allows quality standards to be clearer and stricter, and regulators to have greater knowledge and traceability of each product that enters the market. Through IP, you can establish a record of all products globally, which makes it easier to find possible counterfeit medicines.
9/25/21
Kenyan hospital strikes
Tournament: The Ed Long Invitational at The Hockaday School | Round: 1 | Opponent: Coppell NP | Judge: Berdugo, Erick D. Waithaka et. al , 2-10-2020, "Prolonged health worker strikes in Kenya- perspectives and experiences of frontline health managers and local communities in Kilifi County," International Journal for Equity in Health, https://equityhealthj.biomedcentral.com/articles/10.1186/s12939-020-1131-y
As with other... AND particularly for the poor
11/12/21
Medical Industry Failure
Tournament: The Ed Long Invitational at The Hockaday School | Round: 1 | Opponent: Coppell NP | Judge: Berdugo, Erick Jamaluddin et al., 7-27-2021, "Doctors Strike During COVID-19 Pandemic in Malaysia," Columbia University libraries, https://journals.library.columbia.edu/index.php/bioethics/article/view/8586
Disruptions in delivery... AND serious bodily injury.”